Meet the CCA Clinical Research Team
-
Dr. Scott Purga
Dr. Scott Purga grew up in Schenectady. He graduated Summa Cum Laude from Boston University, College of Arts and Science with dual major in Medical Science and Psychology. While at Boston University, he was enrolled in the seven-year accelerated medical program, was a recipient of the Distinguished Sophomore Award (given to the Top 40 students of the class year), and honored Phi Beta Kappa. He received his medical degree from Boston University School of Medicine, where he was a recipient of the Anthony L.F. Gorman Prize in Physiology and honored Alpha Omega Alpha. While at Boston University, Dr. Purga was an Introduction to Clinical Medical Instructor. Dr. Purga’s post graduate training was at New York Presbyterian Hospital / Weill Cornell Medical Center with a residency in Internal Medicine. He subsequently completed a fellowship in Cardiovascular Disease at Albany Medical Center.
-
Dr. Eugene Pashkovetsky
Dr. Eugene Pashkovetsky graduated Cum Laude from State University of New York Stony Brook with a major in Biology and minor in Chemistry. While at Stoney Brook, he was also on the Dean’s List, a member of Phi Beta Kappa, the Golden Key Honor Society, and National Society of Collegiate Scholars. He received his medical degree from St. George’s University School of Medicine (Grenada, West Indies), where he also taught all materials in Microbiology to medical students. Dr. Pashkovetsky’s post graduate training was at Northwell Health – Lenox Hill Hospital with a residency in Internal Medicine.
-
Dr. Parag Shah
Dr. Parag Shah attended Guy’s Hospital in London, UK where he received his medical degree in 1987. In 1995, he completed a Fellowship in Cardiology at Albany Medical Center in Albany, NY.
Dr. Shah is Board Certified in Cardiology. He is a Fellow of the American College of Cardiology. He is on staff at St. Peter’s Hospital and Albany Medical Center in Albany, NY.
Dr. Shah’s cardiology specialities include: general cardiovascular disease with a special interest in permanent pacemaker implantation and transesophageal echocardiograms.
Current Clinical Research Studies
Capital Cardiology Associates is participating in the following clinical research studies
-
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES).
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires
Read more on this studyNow accepting patients.
-
LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
The primary objective of this study is to collect physiological measurement data and heart failure (HF) event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.
-
A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease
-
The Portico transcatheter aortic valve provides a minimally invasive treatment for patients diagnosed with severe aortic stenosis, an abnormal narrowing of the aortic valve. It is used in patients who may be at a high or extreme risk for open heart surgery
– Not a good candidate for surgical valve replacement
– Patient will either receive portico valve or commercially available valve
*In conjunction with Albany Medical Center
Now accepting new patients! -
o establish the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement(AVR)
-Transcatheter Aortic Valve Replacement (TAVR) -VS- Surgical Aortic Valve Replacement (SAVR)
-10 year study
*In conjunction with Albany Medical Center
Now accepting patients.
-
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry).
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.
Now accepting patients.
-
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.
Learn more about this study.
Please provide the following information so we can notify you when research studies become available for which you might qualify.